Curr Ther Res Clin Exp. 2005 Jul;66(4):323-34. doi: 10.1016/j.curtheres.2005.08.009.
Evaluation of a new five-injection, two-site,intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India.
Current therapeutic research, clinical and experimental
M K Sudarshan, S N Madhusudana, B J Mahendra, D H Ashwath Narayana, M S Ananda Giri, O Popova, H B Vakil
Affiliations
Affiliations
- Department of Community Medicine, Kempegowda Institute of Medical Sciences,Bangalore, India.
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India.
- Clinical Research and Medical Affairs, Chiron Vaccines,Siena, Italy.
- Clinical Research and Medical Affairs, Chiron Vaccines, Mumbai, India.
PMID: 24672132
PMCID: PMC3964532 DOI: 10.1016/j.curtheres.2005.08.009
Abstract
BACKGROUND: Human rabies is an ongoing significant public health problem inmany developing countries, with India reporting the highest incidence of rabies-related deaths (∼20,000 per year). Many people living in India cannot afford the standard IM postexposure prophylaxis (PEP) with cell-culture vaccines, which are administered using a 5-dose regimen developed in Essen, Germany. A potentially less expensive intradermal (ID) regimen, based on the Essen regimen, has been developed at the Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India.
OBJECTIVE: The objective of this study was to compare the immunogenicity and local and systemic tolerability of the KIMS-1D regimen with those of the standard Essen IM regimen in healthy adult volunteers in India.
METHODS: This randomized, open-label, active-controlled trial was conductedat the Antirabies Clinic, Medical College, KIMS. Healthy adult volunteers were randomly assigned to receive purified chick embryo cell vaccine (PCECV) using the KIMS-1D regimen (0.1 mL injected ID at 2 body sites on days 0, 3, 7, 14, and 28 ["2-2-2-2-2"]) or the Essen IM regimen (1 mL injected IM at 1 body site on the same days Subjects were followed up for 365 days by the treating physician and encouraged to voluntarily report any adverse events (AEs). Serum rabies virus-neutralizing antibody (RVNA) concentrations were measured before the first injection on day 0 (baseline) and on days 14, 28, 90, 180, and 365, using the rapid fluorescent focus inhibition test.
RESULTS: Ninety-one subjects were enrolled and included in the tolerabilityand immunogenicity analyses. The ID group comprised 45 subjects (26 men, 19 women; mean [SD] age, 20.84 [1.48] years); the IM group, 46 subjects (28 men, 18 women; mean [SD] age, 21.02 [1.16] years). The most common local AEs were pain at the injection site (2/225 [0.9%] in the ID group and 10/230 [4.3%] in the IM group; P < 0.006) and itching at the injection site (5/225 [2.2%] in the ID group and none in the IM group; P = 0.026). All of the AEs were transient and resolved without the need for medication. All subjects had serum RVNA concentrations ≥0.5 IU/mL-considered protective by the World Health Organization-at all follow-up visits. However, the mean RVNA concentrations in the IM group were significantly higher compared with those in the ID group from days 14 to 365 (all, P < 0.001).
CONCLUSION: In this study in healthy volunteers, PEP with PCECV administered using the KIMS-ID regimen was well tolerated and immunologically efficacious for 365 days. Adequate RVNA levels were maintained with the KIMS-ID regimen from days 14 to 365, although these levels were significantly lower than those achieved in the group receiving the Essen IM regimen (all, P < 0.001).
Keywords: KIMS-ID regimen; intradermal rabies vaccination; rabies; randomizedcontrolled trial
References
- Pediatr Infect Dis J. 1998 Nov;17(11):1001-7 - PubMed
- Vaccine. 1998 Oct;16(16):1559-62 - PubMed
- Bull World Health Organ. 2000;78(5):693-8 - PubMed
- Clin Infect Dis. 2002 Feb 1;34(3):404-6 - PubMed
- Lancet. 1990 Apr 14;335(8694):896-8 - PubMed
- Int J Infect Dis. 2004 May;8(3):175-9 - PubMed
- Natl Med J India. 2001 May-Jun;14(3):145-7 - PubMed
- Vaccine. 2005 Jun 10;23(30):3902-7 - PubMed
- MMWR Morb Mortal Wkly Rep. 1984 Jul 20;33(28):393-402, 407-8 - PubMed
- J Epidemiol. 1999 Aug;9(4):209-15 - PubMed
- World Health Organ Tech Rep Ser. 1992;824:1-84 - PubMed
Publication Types